» Articles » PMID: 38447592

Diffuse Hemispheric Glioma with H3 P.K28M (K27M) Mutation: Unusual Non-midline Presentation of Diffuse Midline Glioma, H3 K27M-altered?

Abstract

Diffuse midline glioma, H3 K27-altered (DMG-H3 K27) is an aggressive group of diffuse gliomas that predominantly occurs in pediatric patients, involves midline structures, and displays loss of H3 p.K28me3 (K27me3) expression by immunohistochemistry and characteristic genetic/epigenetic profile. Rare examples of a diffuse glioma with an H3 p.K28M (K27M) mutation and without involvement of the midline structures, so-called "diffuse hemispheric glioma with H3 p.K28M (K27M) mutation" (DHG-H3 K27), have been reported. Herein, we describe 2 additional cases of radiologically confirmed DHG-H3 K27 and summarize previously reported cases. We performed histological, immunohistochemical, molecular, and DNA methylation analysis and provided clinical follow-up in both cases. Overall, DHG-H3 K27 is an unusual group of diffuse gliomas that shows similar clinical, histopathological, genomic, and epigenetic features to DMG-H3 K27 as well as enrichment for activating alterations in MAPK pathway genes. These findings suggest that DHG-H3 K27 is closely related to DMG-H3 K27 and may represent an unusual presentation of DMG-H3 K27 without apparent midline involvement and with frequent MAPK pathway activation. Detailed reports of additional cases with clinical follow-up will be important to expand our understanding of this unusual group of diffuse gliomas and to better define the clinical outcome and how to classify DHG-H3 K27.

Citing Articles

Clinico-Pathological Features of Diffuse Midline Glioma, H3 K27-Altered in Adults: A Comprehensive Review of the Literature with an Additional Single-Institution Case Series.

Broggi G, Salzano S, Failla M, Barbagallo G, Certo F, Zanelli M Diagnostics (Basel). 2024; 14(23).

PMID: 39682526 PMC: 11640674. DOI: 10.3390/diagnostics14232617.


Methylation assay in KMT2B-related dystonia: a novel diagnostic validation tool.

da Silva Carvalho G, de Gusmao C, Wolff B, Vieira L, de Oliveira Y, Costa M Clin Epigenetics. 2024; 16(1):169.

PMID: 39587624 PMC: 11590325. DOI: 10.1186/s13148-024-01780-1.


H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications.

Angelico G, Mazzucchelli M, Attanasio G, Tinnirello G, Farina J, Zanelli M Cancers (Basel). 2024; 16(20).

PMID: 39456545 PMC: 11506073. DOI: 10.3390/cancers16203451.


Fulminant leptomeningeal disease diagnosed as comutant H3F3A and FGFR diffuse midline glioma.

Benistant L, Reita D, Schenck M, Castelain V, Cebula H, Lhermitte B Ann Clin Transl Neurol. 2024; 11(11):3037-3041.

PMID: 39440520 PMC: 11572734. DOI: 10.1002/acn3.52180.

References
1.
Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

2.
Fujioka Y, Hata N, Hatae R, Suzuki S, Sangatsuda Y, Nakahara Y . A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient. Neuropathology. 2019; 40(1):99-103. DOI: 10.1111/neup.12609. View

3.
Bady P, Sciuscio D, Diserens A, Bloch J, van den Bent M, Marosi C . MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012; 124(4):547-60. PMC: 3444709. DOI: 10.1007/s00401-012-1016-2. View

4.
Pun M, Pratt D, Nano P, Joshi P, Jiang L, Englinger B . Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Acta Neuropathol Commun. 2023; 11(1):25. PMC: 9912509. DOI: 10.1186/s40478-023-01514-z. View

5.
Tomita Y, Shimazu Y, Somasundaram A, Tanaka Y, Takata N, Ishi Y . A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M. Glia. 2022; 70(9):1681-1698. PMC: 9546478. DOI: 10.1002/glia.24189. View